Could an immune treatment ease long COVID brain fog?

NCT ID NCT05350774

ENROLLING_BY_INVITATION Symptom relief Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 07, 2026 · Updated 13 times

Summary

This study tests whether a treatment called IVIG (intravenous immunoglobulin) can help with ongoing neurological symptoms after COVID-19, like dizziness, trouble walking, or memory problems. About 45 adults who had COVID-19 at least 12 weeks ago will receive either IVIG or a placebo (saline) for 5 days, then switch to the other. Researchers will check if symptoms improve after two weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IV immunoglobulin (IVIG)
What this could lead to: If it works, this could point toward a treatment for neurological Long COVID symptoms, such as dizziness and memory problems.
What could go wrong: This is a small, early-stage trial with only 45 participants, so results may not apply to everyone. IVIG can cause side effects like headache or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MICROVASCULAR THROMBOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 long COVID-19 Neuroinflammatory Diseases neuronitis thrombotic microangiopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MICROVASCULAR THROMBOSIS NEUROINFLAMMATION SYSTEMIC INFLAMMATION

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.